Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy
- PMID: 20700802
- DOI: 10.1007/s10384-010-0807-z
Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy
Abstract
Purpose: To evaluate the anatomical and functional outcomes of pars plana vitrectomy (PPV) in pseudophakic retinal detachment (RD) complicated with proliferative vitreoretinopathy (PVR) without previous scleral buckling (SB) or vitrectomy, both with and without triamcinolone acetonide (TA) assistance.
Methods: In this retrospective, interventional, comparative case series, 72 pseudophakic eyes with RD with PVR grade C1 or greater underwent PPV either with (group 1, n = 40) or without (group 2, n = 32) TA assistance. Eyes with a minimum of 6 months of follow-up were evaluated. Main outcome measures were reattachment, redetachment, complication rate, and changes in visual acuity (VA).
Results: The mean follow-up period was 14.57 +/- 8.55 months. Single-surgery and final reattachment rates were 87.50% and 95% in group 1, and 78.12 % and 96.87% in group 2, (P = 0.349, P = 1.000). Redetachment rates were 12.50% in group 1 and 21.87% group 2 (P = 0.349). In both groups the mean VA increased significantly in postoperative week 1 and in all control visits (P< 0.001) with no difference in complication rate (P > 0.05).
Conclusions: In this study PPV with TA assistance resulted in a lower, albeit statistically insignificant, redetachment rate in the treatment of RD complicated with PVR compared to PPV without TA assistance in eyes without previous SB or PPV. Visual acuity improved in 72% of eyes in both groups. Intraoperative and postoperative complication rates were also similar.
Similar articles
-
Primary pars plana vitrectomy versus scleral buckle surgery for the treatment of pseudophakic retinal detachment: a randomized clinical trial.Retina. 2005 Dec;25(8):957-64. doi: 10.1097/00006982-200512000-00001. Retina. 2005. PMID: 16340523 Clinical Trial.
-
Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment.Ophthalmology. 2006 Nov;113(11):2033-40. doi: 10.1016/j.ophtha.2006.05.038. Ophthalmology. 2006. PMID: 17074564
-
Inferior retinotomy and silicone oil tamponade for recurrent inferior retinal detachment and grade C PVR in eyes previously treated with pars plana vitrectomy or scleral buckle.BMC Ophthalmol. 2015 Dec 9;15:173. doi: 10.1186/s12886-015-0167-z. BMC Ophthalmol. 2015. PMID: 26645589 Free PMC article.
-
Outcomes and Complications of Pars Plana Vitrectomy for Tractional Retinal Detachment in People With Diabetes: A Systematic Review and Meta-analysis.JAMA Ophthalmol. 2023 Feb 1;141(2):186-195. doi: 10.1001/jamaophthalmol.2022.5817. JAMA Ophthalmol. 2023. PMID: 36633878 Free PMC article.
-
Vitreoschisis-induced vitreous cortex remnants in proliferative vitreoretinopathy: A comprehensive review from basic research to clinical practice.Acta Ophthalmol. 2024 Dec;102(8):859-880. doi: 10.1111/aos.16755. Epub 2024 Sep 11. Acta Ophthalmol. 2024. PMID: 39262083 Review.
Cited by
-
Evaluation of a steroid delivery system to mitigate the severity of proliferative vitreoretinopathy in a minipig model.Front Ophthalmol (Lausanne). 2023 Nov 17;3:1222689. doi: 10.3389/fopht.2023.1222689. eCollection 2023. Front Ophthalmol (Lausanne). 2023. PMID: 38982997 Free PMC article.
-
Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy.Graefes Arch Clin Exp Ophthalmol. 2021 Oct;259(10):2913-2917. doi: 10.1007/s00417-021-05206-z. Epub 2021 Apr 26. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33900444
-
Steroid Drugs as an Adjunct for Reducing the Incidence of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment Surgery: A Meta-Analysis of Randomized Controlled Studies.Ophthalmic Res. 2023;66(1):599-610. doi: 10.1159/000529451. Epub 2023 Feb 8. Ophthalmic Res. 2023. PMID: 36754031 Free PMC article.
-
Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.Int Ophthalmol. 2018 Aug;38(4):1365-1378. doi: 10.1007/s10792-017-0594-3. Epub 2017 Jun 21. Int Ophthalmol. 2018. PMID: 28639085
-
Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis.Drug Des Devel Ther. 2015 Mar 6;9:1393-400. doi: 10.2147/DDDT.S80983. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25834397 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous